Baidu
map

Allergy Asthma Immunol Res:慢性鼻窦炎不同亚型中鼻组织特征性细胞因子研究

2019-02-03 AlexYang MedSci原创

慢性鼻窦炎(CRS)的内分型在过去十年已经建立。然而,CRS准确的免疫情况仍旧还存在矛盾,原因是其具有很多的免疫异质性。因此,最近有研究人员根据慢性鼻窦炎不同鼻组织调查了不同的免疫调节因子情况,并做了相关比较。研究人员从对照、不具有NP的CRS患者(CRSsNP)和具有NP的CRS患者(CRSwNP)中分别搜集了钩突粘膜(UP)和鼻息肉(NP)组织。研究发现,在嗜酸性NP患者中,特征性炎症调控因子

慢性鼻窦炎(CRS)的内分型在过去十年已经建立。然而,CRS准确的免疫情况仍旧还存在矛盾,原因是其具有很多的免疫异质性。因此,最近有研究人员根据慢性鼻窦炎不同鼻组织调查了不同的免疫调节因子情况,并做了相关比较。

研究人员从对照、不具有NP的CRS患者(CRSsNP)和具有NP的CRS患者(CRSwNP)中分别搜集了钩突粘膜(UP)和鼻息肉(NP)组织。研究发现,在嗜酸性NP患者中,特征性炎症调控因子包括白介素-5(IL-5)、C-C基序趋化因子配体-24(CCL-24)、单核细胞趋化蛋白-4(MCP-4)和血管细胞粘附因子-1(VCAM-1),而非嗜酸性NP患者中的特征性因子包括IL-17A、IL-1β和基质金属肽酶-9(MMP-9)。尽管在嗜酸性和非嗜酸性NP之间,炎症细胞因子存在差异,在同一受试者中,与UP相比,NP中的IL-5、CCL-11、IL-23、IL-2Rα、VCAM-1、MMP-3和MMP-9均上调。在主成分分析中(PCA),研究人员观察到Th2免疫响应在区分CRS亚型不同鼻组织中是有用的,并且在非嗜酸性NP和嗜酸性NP之间具有部分重叠。

最后,研究人员指出,不考虑CRS亚型且与UP相比,NP中上调的调节因子为Th2相关的,而不同的NP亚型中,特征性标记是不同的。不考虑CRSwNP亚型,他们的发现表明了Th2炎症响应因子在NP的发展过程中具有作用。

原始出处:

Kim DK, Eun KM, Kim MK et al. Comparison Between Signature Cytokines of Nasal Tissues in Subtypes of Chronic Rhinosinusitis. Allergy Asthma Immunol Res. Mar 2019.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1977138, encodeId=d0ce19e7138af, content=<a href='/topic/show?id=0081289832' target=_blank style='color:#2F92EE;'>#asthma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2898, encryptionId=0081289832, topicName=asthma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b30126, createdName=skhzy, createdTime=Sun Jan 12 01:03:00 CST 2020, time=2020-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1809585, encodeId=54e9180958588, content=<a href='/topic/show?id=6cd683e603b' target=_blank style='color:#2F92EE;'>#胞因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83760, encryptionId=6cd683e603b, topicName=胞因子)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/017ED6AFEB45F49165298113DDC0656A/100, createdBy=84182500174, createdName=ms7019579240139182, createdTime=Sun Mar 31 09:03:00 CST 2019, time=2019-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1711801, encodeId=2a341e118012f, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Thu Sep 05 13:03:00 CST 2019, time=2019-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1283619, encodeId=9f69128361970, content=<a href='/topic/show?id=2c00e784416' target=_blank style='color:#2F92EE;'>#细胞因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77844, encryptionId=2c00e784416, topicName=细胞因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Tue Feb 05 11:03:00 CST 2019, time=2019-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329204, encodeId=0bee13292049c, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Tue Feb 05 11:03:00 CST 2019, time=2019-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1351391, encodeId=2084135139148, content=<a href='/topic/show?id=be7453e38d2' target=_blank style='color:#2F92EE;'>#慢性鼻窦炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53738, encryptionId=be7453e38d2, topicName=慢性鼻窦炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Feb 05 11:03:00 CST 2019, time=2019-02-05, status=1, ipAttribution=)]
    2020-01-12 skhzy
  2. [GetPortalCommentsPageByObjectIdResponse(id=1977138, encodeId=d0ce19e7138af, content=<a href='/topic/show?id=0081289832' target=_blank style='color:#2F92EE;'>#asthma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2898, encryptionId=0081289832, topicName=asthma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b30126, createdName=skhzy, createdTime=Sun Jan 12 01:03:00 CST 2020, time=2020-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1809585, encodeId=54e9180958588, content=<a href='/topic/show?id=6cd683e603b' target=_blank style='color:#2F92EE;'>#胞因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83760, encryptionId=6cd683e603b, topicName=胞因子)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/017ED6AFEB45F49165298113DDC0656A/100, createdBy=84182500174, createdName=ms7019579240139182, createdTime=Sun Mar 31 09:03:00 CST 2019, time=2019-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1711801, encodeId=2a341e118012f, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Thu Sep 05 13:03:00 CST 2019, time=2019-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1283619, encodeId=9f69128361970, content=<a href='/topic/show?id=2c00e784416' target=_blank style='color:#2F92EE;'>#细胞因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77844, encryptionId=2c00e784416, topicName=细胞因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Tue Feb 05 11:03:00 CST 2019, time=2019-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329204, encodeId=0bee13292049c, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Tue Feb 05 11:03:00 CST 2019, time=2019-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1351391, encodeId=2084135139148, content=<a href='/topic/show?id=be7453e38d2' target=_blank style='color:#2F92EE;'>#慢性鼻窦炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53738, encryptionId=be7453e38d2, topicName=慢性鼻窦炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Feb 05 11:03:00 CST 2019, time=2019-02-05, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1977138, encodeId=d0ce19e7138af, content=<a href='/topic/show?id=0081289832' target=_blank style='color:#2F92EE;'>#asthma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2898, encryptionId=0081289832, topicName=asthma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b30126, createdName=skhzy, createdTime=Sun Jan 12 01:03:00 CST 2020, time=2020-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1809585, encodeId=54e9180958588, content=<a href='/topic/show?id=6cd683e603b' target=_blank style='color:#2F92EE;'>#胞因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83760, encryptionId=6cd683e603b, topicName=胞因子)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/017ED6AFEB45F49165298113DDC0656A/100, createdBy=84182500174, createdName=ms7019579240139182, createdTime=Sun Mar 31 09:03:00 CST 2019, time=2019-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1711801, encodeId=2a341e118012f, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Thu Sep 05 13:03:00 CST 2019, time=2019-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1283619, encodeId=9f69128361970, content=<a href='/topic/show?id=2c00e784416' target=_blank style='color:#2F92EE;'>#细胞因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77844, encryptionId=2c00e784416, topicName=细胞因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Tue Feb 05 11:03:00 CST 2019, time=2019-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329204, encodeId=0bee13292049c, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Tue Feb 05 11:03:00 CST 2019, time=2019-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1351391, encodeId=2084135139148, content=<a href='/topic/show?id=be7453e38d2' target=_blank style='color:#2F92EE;'>#慢性鼻窦炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53738, encryptionId=be7453e38d2, topicName=慢性鼻窦炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Feb 05 11:03:00 CST 2019, time=2019-02-05, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1977138, encodeId=d0ce19e7138af, content=<a href='/topic/show?id=0081289832' target=_blank style='color:#2F92EE;'>#asthma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2898, encryptionId=0081289832, topicName=asthma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b30126, createdName=skhzy, createdTime=Sun Jan 12 01:03:00 CST 2020, time=2020-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1809585, encodeId=54e9180958588, content=<a href='/topic/show?id=6cd683e603b' target=_blank style='color:#2F92EE;'>#胞因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83760, encryptionId=6cd683e603b, topicName=胞因子)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/017ED6AFEB45F49165298113DDC0656A/100, createdBy=84182500174, createdName=ms7019579240139182, createdTime=Sun Mar 31 09:03:00 CST 2019, time=2019-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1711801, encodeId=2a341e118012f, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Thu Sep 05 13:03:00 CST 2019, time=2019-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1283619, encodeId=9f69128361970, content=<a href='/topic/show?id=2c00e784416' target=_blank style='color:#2F92EE;'>#细胞因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77844, encryptionId=2c00e784416, topicName=细胞因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Tue Feb 05 11:03:00 CST 2019, time=2019-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329204, encodeId=0bee13292049c, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Tue Feb 05 11:03:00 CST 2019, time=2019-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1351391, encodeId=2084135139148, content=<a href='/topic/show?id=be7453e38d2' target=_blank style='color:#2F92EE;'>#慢性鼻窦炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53738, encryptionId=be7453e38d2, topicName=慢性鼻窦炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Feb 05 11:03:00 CST 2019, time=2019-02-05, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1977138, encodeId=d0ce19e7138af, content=<a href='/topic/show?id=0081289832' target=_blank style='color:#2F92EE;'>#asthma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2898, encryptionId=0081289832, topicName=asthma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b30126, createdName=skhzy, createdTime=Sun Jan 12 01:03:00 CST 2020, time=2020-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1809585, encodeId=54e9180958588, content=<a href='/topic/show?id=6cd683e603b' target=_blank style='color:#2F92EE;'>#胞因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83760, encryptionId=6cd683e603b, topicName=胞因子)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/017ED6AFEB45F49165298113DDC0656A/100, createdBy=84182500174, createdName=ms7019579240139182, createdTime=Sun Mar 31 09:03:00 CST 2019, time=2019-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1711801, encodeId=2a341e118012f, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Thu Sep 05 13:03:00 CST 2019, time=2019-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1283619, encodeId=9f69128361970, content=<a href='/topic/show?id=2c00e784416' target=_blank style='color:#2F92EE;'>#细胞因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77844, encryptionId=2c00e784416, topicName=细胞因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Tue Feb 05 11:03:00 CST 2019, time=2019-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329204, encodeId=0bee13292049c, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Tue Feb 05 11:03:00 CST 2019, time=2019-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1351391, encodeId=2084135139148, content=<a href='/topic/show?id=be7453e38d2' target=_blank style='color:#2F92EE;'>#慢性鼻窦炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53738, encryptionId=be7453e38d2, topicName=慢性鼻窦炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Feb 05 11:03:00 CST 2019, time=2019-02-05, status=1, ipAttribution=)]
    2019-02-05 膀胱癌
  6. [GetPortalCommentsPageByObjectIdResponse(id=1977138, encodeId=d0ce19e7138af, content=<a href='/topic/show?id=0081289832' target=_blank style='color:#2F92EE;'>#asthma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2898, encryptionId=0081289832, topicName=asthma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b30126, createdName=skhzy, createdTime=Sun Jan 12 01:03:00 CST 2020, time=2020-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1809585, encodeId=54e9180958588, content=<a href='/topic/show?id=6cd683e603b' target=_blank style='color:#2F92EE;'>#胞因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83760, encryptionId=6cd683e603b, topicName=胞因子)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/017ED6AFEB45F49165298113DDC0656A/100, createdBy=84182500174, createdName=ms7019579240139182, createdTime=Sun Mar 31 09:03:00 CST 2019, time=2019-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1711801, encodeId=2a341e118012f, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Thu Sep 05 13:03:00 CST 2019, time=2019-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1283619, encodeId=9f69128361970, content=<a href='/topic/show?id=2c00e784416' target=_blank style='color:#2F92EE;'>#细胞因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77844, encryptionId=2c00e784416, topicName=细胞因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Tue Feb 05 11:03:00 CST 2019, time=2019-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329204, encodeId=0bee13292049c, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Tue Feb 05 11:03:00 CST 2019, time=2019-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1351391, encodeId=2084135139148, content=<a href='/topic/show?id=be7453e38d2' target=_blank style='color:#2F92EE;'>#慢性鼻窦炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53738, encryptionId=be7453e38d2, topicName=慢性鼻窦炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Feb 05 11:03:00 CST 2019, time=2019-02-05, status=1, ipAttribution=)]

相关资讯

Int Forum Allergy Rhinol:11年之间中国鼻息肉慢性鼻窦炎患者的临床和组织特性变化

传统上认为,中国鼻息肉慢性鼻窦炎(CRSwNP)患者要比北美和欧洲患者具有更少的嗜酸性细胞和更多的中性粒细胞炎症。然而,炎症模式可能随着时间而变化。最近,有研究人员分析了中国患者CRSwNP临床和组织特性随着时间变化的趋势情况。研究包括了2003年到2005年间的115名连续性CRSwNP患者和2014年到2016年114名连续性CRSwNP患者。研究发现,在11年研究期间,嗜酸性粒细胞在鼻息肉组

盘点:鼻部疾病研究进展

【1】Environ Pollut:大气中的粗细颗粒能够对鼻腔和支气管上皮细胞产生不同的影响和诱发不同的免疫响应大气中的颗粒物质(PM)在流行病学上能够加速恶化呼吸和免疫健康,包括过敏性鼻炎(AR)和支气管哮喘(BA)。尽管精细的和粗大的颗粒能够影响呼吸道,然而他们对上呼吸道和下呼吸道以及免疫系统的影响差异、它们潜在的机制和对健康造成不良影响的组成仍旧还没有完全的阐释。最近,有研究人员利用旋流

2018 EAACI意见书:NSAID加重呼吸系统疾病的诊断和管理

2018年9月,欧洲变应性反应与临床免疫学会(EAACI)发布了关于NSAID加重呼吸系统疾病的诊断和管理意见书,NSAID加重呼吸系统疾病(N-ERD)是一种慢性嗜酸性炎症性呼吸系统疾病,主要发生于哮喘和/或慢性鼻窦炎伴鼻息肉患者,其症状因为应用非甾体抗炎药而加重。本文主要针对这些患者的诊断和管理提出共识建议。

Med Sci Monit:感官性听力损失与外毛细胞损伤引起的慢性鼻窦炎有关吗?

感官听力损失石油内耳的缺陷引起。研究中,研究人员调查了慢性鼻窦炎、外毛细胞损伤和感官听力损失之间的相关性。研究包括了103符合入选标砖的患者,并且分配到慢性鼻窦炎组(n=82)和单纯鼻中隔偏曲组(n=21)。研究发现,听力损失在单纯鼻中隔偏曲组中的比例要显著比慢性鼻炎组更低(4.76%, 1/21 vs. 24.39%, 20/82, P<0.05),其中15名慢性鼻窦炎患者(75%,15/

Eur Arch Otorhinolaryngol: 过敏性鼻炎对鼻粘膜重建的不同影响研究

过敏性鼻炎(AR)已经报道与慢性鼻窦炎(CRS)相关。最近,有研究人员调查了AR对CRS鼻粘膜重建的影响。研究人员将募集的患者分成不同的小组:具有鼻息肉(NP)和过敏性鼻炎(AR)的CRS患者(CRSwNPwAR,n=20)、具有NP,不具有AR的CRS患者(CRSwNPsAR; n?=?20)、不具有NP,具有AR的CRS患者(CRSsNPwAR; n?=?20)、不具有NP和AR的CRS患者(

J Allergy Clin Immunol:慢性鼻窦炎在普通人群中的患病率调查

慢性鼻窦炎在流行病学研究中的患病率为5-12%。但是由于与其他疾病,比如过敏性鼻炎重叠,因此该数据的评估可能偏高。最近,有研究人员根据EPOS(欧洲关于鼻窦炎和鼻息肉的文件)和鼻窦浑浊影像学,对基于CRS的流行病学患病率进行了评估。研究人员对那些经历了脑部CT或者MRI的受试者进行了相关调查,包括填写GA2LEN调查(包含EPOS症状标准)。研究人员根据Lund-Mackay (LM)评分系统对扫

Baidu
map
Baidu
map
Baidu
map